APOE Notes

2026-06-19

Manual notes created because provider deep research was unavailable in this run.
timeout 180 just deep-research-falcon human APOE --fallback perplexity-lite
stayed silent and timed out without writing an artifact. Publication caching was
refreshed separately with just fetch-gene-pmids human APOE and confirmed all
104 APOE review PMIDs were already cached. Per project instructions, no
provider-named deep-research file was written manually.

Core biology: APOE encodes apolipoprotein E, a secreted exchangeable
apolipoprotein whose primary function is lipid and lipoprotein transport.
ABCA1-dependent APOE lipidation supports cholesterol and phospholipid efflux
PMID:11162594. The C-terminal lipid-binding
domain is sufficient for ABCA1 lipid efflux and HDL particle assembly
PMID:17305370.

Lipoprotein clearance: APOE acts as a receptor/proteoglycan ligand on
lipoprotein particles. LRP mediates uptake and lysosomal hydrolysis of
cholesteryl esters in apoE-enriched lipoproteins PMID:2762297. Hepatic HSPG
clearance of triglyceride-rich lipoproteins is mediated in part by ApoE
PMID:23676495.

CNS context: APOE also mediates glial/CNS lipid transport. Astrocytes expressing
human APOE isoforms release cholesterol and phospholipids into HDL-like
particles PMID:12042316. This supports retaining CNS lipid-transport annotations while
keeping downstream synaptic, neurite, and behavior annotations as non-core
phenotypes.

Amyloid and immune interactions: APOE has credible Alzheimer-relevant
interactions with amyloid-beta, tau, TREM2/LILRB4, extracellular vesicles, and
other partners, but these should not displace the core lipid/lipoprotein
function. ApoE affects amyloid-beta oligomer/fibril growth PMID:25207746 and APOE-containing lipoprotein particles can act
as TREM2 ligands PMID:27477018. These were retained as non-core or marked over-annotated when the term
was only generic protein binding.

Knowledge gaps to curate:

• Which APOE receptor/proteoglycan interactions should be represented by
  particle class, receptor family, and tissue, rather than as generic receptor
  binding?
• Which CNS APOE phenotypes are direct consequences of normal glial lipid
  transport, and which are downstream disease-model effects involving amyloid,
  tau, inflammation, or synapses?
• Which extracellular-vesicle and multivesicular-body APOE pools are normal
  physiological lipid-transport pools versus specialized contexts such as PMEL
  amyloid formation in pigment cells?

Review update: completed first-pass review of all 293 seeded GO annotations.
Final action distribution after validation: 145 ACCEPT, 120 KEEP_AS_NON_CORE,
and 28 MARK_AS_OVER_ANNOTATED. just validate human APOE passes cleanly. The
reference title for PMID:1530612 was aligned to the validator's cached parser
output, which truncates at the ---- sequence in the publication title; the
publication cache itself was not edited.

2026-06-20 second-pass audit

The second-pass audit added manual reference_review metadata for the key APOE references supporting ABCA1-dependent lipid efflux, astrocyte APOE lipoprotein release, LRP-mediated uptake of apoE-enriched particles, amyloid-beta binding/aggregation effects, and TREM2-mediated microglial uptake of APOE-containing amyloid-lipoprotein complexes. No annotation action changes were needed: the core remains lipid/lipoprotein transport and receptor-mediated particle handling, while amyloid, synaptic, immune, and disease-model outcomes remain non-core or over-annotated when they do not describe the primary evolved APOE function.